Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial - PubMed (original) (raw)
Clinical Trial
Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial
A H Liem et al. Int J Cardiol. 2004 Feb.
Abstract
Background: Folic acid is assumed to have favourable effects on vascular endothelium, directly as well as indirectly through its effect on homocysteine metabolism. However, the clinical value of folic acid in secondary prevention after acute myocardial infarction (MI) has never been tested. Thus, a randomised, open-label, multicentre trial was performed in order to study the effect of folic acid 5 mg o.d. when added to statin therapy on the incidence of recurrent major clinical events up to 1 year post-MI.
Methods: A total of 283 patients with a total cholesterol >6.5 mmol/l (251 mg/dl) (mean 7.3 mmol/l) were included. All patients received 40 fluvastatin. In 140 of the 283 patients, folic acid (5 mg o.d.) was instituted at discharge, and the remaining 143 patients served as controls. Other secondary prevention measures for both groups were advocated. The primary endpoint was a composite consisting of all vascular events, including death, recurrent MI, strokes, and unplanned invasive coronary interventions.
Results: At baseline, the two groups were well-matched for all clinical and demographic parameters. After 1 year of treatment, no difference was noticed in the primary endpoint between the two groups. These endpoints occurred in 43 patients (31%) in the folic acid group, as opposed to 45 patients (31%) in the control group. All separate cardiovascular events were also equally distributed between both groups. Total cholesterol levels decreased to a similar extent in the two groups (to 5.5 and 5.7 mmol/l, in folic acid and control groups, respectively).
Conclusions: In this medium-size pilot study, folic acid did not demonstrate any beneficial additive effects on cardiovascular mortality or morbidity in post-MI patients with hypercholesterolemia who were treated with statin therapy. Larger trials, possibly targeting at selected populations, must be awaited before definitive conclusions regarding the potentially favourable effects of folic acid supplementation in secondary prevention can be drawn.
Similar articles
- Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X. Alvarez-Sala LA, et al. Clin Ther. 2008 Jan;30(1):84-97. doi: 10.1016/j.linthera.2008.01.013. Clin Ther. 2008. PMID: 18343245 Clinical Trial. - A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH).
MacMahon M, Kirkpatrick C, Cummings CE, Clayton A, Robinson PJ, Tomiak RH, Liu M, Kush D, Tobert J. MacMahon M, et al. Nutr Metab Cardiovasc Dis. 2000 Aug;10(4):195-203. Nutr Metab Cardiovasc Dis. 2000. PMID: 11079257 Clinical Trial. - Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS, Mikhailidis DP. Daskalopoulou SS, et al. Curr Med Res Opin. 2006 Mar;22(3):511-28. doi: 10.1185/030079906X89856. Curr Med Res Opin. 2006. PMID: 16574035 Review. - When statin therapy stops: implications for the patient.
Daskalopoulou SS. Daskalopoulou SS. Curr Opin Cardiol. 2009 Sep;24(5):454-60. doi: 10.1097/HCO.0b013e32832ebf92. Curr Opin Cardiol. 2009. PMID: 19574923 Review.
Cited by
- Homocysteine lowering interventions for preventing cardiovascular events.
Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G. Martí-Carvajal AJ, et al. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006612. doi: 10.1002/14651858.CD006612.pub2. Cochrane Database Syst Rev. 2009. PMID: 19821378 Free PMC article. Updated. Review. - Homocysteine-lowering interventions for preventing cardiovascular events.
Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Martí-Carvajal AJ, et al. Cochrane Database Syst Rev. 2017 Aug 17;8(8):CD006612. doi: 10.1002/14651858.CD006612.pub5. Cochrane Database Syst Rev. 2017. PMID: 28816346 Free PMC article. Review. - Statins and micronutrients: unanswered questions.
McKee M, Moat SJ, McDowell I. McKee M, et al. J R Soc Med. 2004 Oct;97(10):459-60. doi: 10.1177/0141076809701001. J R Soc Med. 2004. PMID: 15459254 Free PMC article. No abstract available. - Failure of vitamin supplementation to lower the risk of recurrent stroke.
Adams HP Jr. Adams HP Jr. Curr Neurol Neurosci Rep. 2011 Feb;11(1):1-5. doi: 10.1007/s11910-010-0152-0. Curr Neurol Neurosci Rep. 2011. PMID: 20963642 No abstract available. - Folic Acid in Stroke Prevention in Countries without Mandatory Folic Acid Food Fortification: A Meta-Analysis of Randomized Controlled Trials.
Hsu CY, Chiu SW, Hong KS, Saver JL, Wu YL, Lee JD, Lee M, Ovbiagele B. Hsu CY, et al. J Stroke. 2018 Jan;20(1):99-109. doi: 10.5853/jos.2017.01522. Epub 2018 Jan 31. J Stroke. 2018. PMID: 29402063 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical